GTX (GTXI) Shares Down 7.7%
GTx, Inc. (NASDAQ:GTXI)’s share price traded down 7.7% during mid-day trading on Friday . The company traded as low as $1.50 and last traded at $1.55. 614,986 shares traded hands during trading, a decline of 18% from the average session volume of 747,045 shares. The stock had previously closed at $1.68.
A number of equities analysts have issued reports on the company. Zacks Investment Research raised GTX from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Tuesday, October 16th. ValuEngine lowered GTX from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Stifel Nicolaus lowered GTX from a “buy” rating to a “hold” rating in a research note on Friday, September 21st. Robert W. Baird lowered GTX from an “outperform” rating to a “neutral” rating and set a $17.00 price target for the company. in a research note on Friday, September 21st. Finally, BidaskClub lowered GTX from a “buy” rating to a “hold” rating in a research note on Thursday, September 20th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.25.
GTX (NASDAQ:GTXI) last announced its quarterly earnings data on Monday, October 22nd. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). As a group, analysts anticipate that GTx, Inc. will post -1.65 earnings per share for the current fiscal year.
GTX Company Profile (NASDAQ:GTXI)
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.